Firebrick Pharma Ltd (AU:FRE) — Market Cap & Net Worth
Market Cap & Net Worth: Firebrick Pharma Ltd (FRE)
Firebrick Pharma Ltd (AU:FRE) has a market capitalization of $9.47 Million (AU$13.38 Million) as of May 6, 2026. Listed on the AU stock exchange, this Australia-based company holds position #26983 globally and #1352 in its home market, demonstrating a -1.85% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Firebrick Pharma Ltd's stock price AU$0.05 by its total outstanding shares 252479085 (252.48 Million). Analyse cash efficiency ratio of Firebrick Pharma Ltd to see how efficiently the company converts income to cash.
Firebrick Pharma Ltd Market Cap History: 2022 to 2026
Firebrick Pharma Ltd's market capitalization history from 2022 to 2026. Data shows change from $41.09 Million to $9.47 Million (-41.69% CAGR).
Firebrick Pharma Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Firebrick Pharma Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
32.27x
Firebrick Pharma Ltd's market cap is 32.27 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $41.09 Million | $4.12K | -$3.80 Million | 9963.23x | N/A |
| 2023 | $8.93 Million | $830.00 | -$6.80 Million | 10761.75x | N/A |
| 2024 | $11.08 Million | $14.52K | -$1.18 Million | 762.70x | N/A |
| 2025 | $9.47 Million | $293.42K | -$2.63 Million | 32.27x | N/A |
Competitor Companies of FRE by Market Capitalization
Companies near Firebrick Pharma Ltd in the global market cap rankings as of May 6, 2026.
Key companies related to Firebrick Pharma Ltd by market ranking:
- Eli Lilly and Company (NYSE:LLY): Ranked #16 globally with a market cap of $885.06 Billion USD.
- Eli Lilly and Company (SA:LILY34): Ranked #17 globally with a market cap of $853.51 Billion USD ( R$4.35 Trillion BRL).
- Johnson & Johnson (NYSE:JNJ): Ranked #23 globally with a market cap of $543.42 Billion USD.
- AbbVie Inc (NYSE:ABBV): Ranked #37 globally with a market cap of $364.44 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #16 | Eli Lilly and Company | NYSE:LLY | $885.06 Billion | $988.87 |
| #17 | Eli Lilly and Company | SA:LILY34 | $853.51 Billion | R$153.70 |
| #23 | Johnson & Johnson | NYSE:JNJ | $543.42 Billion | $225.55 |
| #37 | AbbVie Inc | NYSE:ABBV | $364.44 Billion | $206.11 |
Firebrick Pharma Ltd Historical Marketcap From 2022 to 2026
Between 2022 and today, Firebrick Pharma Ltd's market cap moved from $41.09 Million to $ 9.47 Million, with a yearly change of -41.69%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | AU$9.47 Million | 0.00% |
| 2025 | AU$9.47 Million | -14.52% |
| 2024 | AU$11.08 Million | +24.00% |
| 2023 | AU$8.93 Million | -78.26% |
| 2022 | AU$41.09 Million | -- |
End of Day Market Cap According to Different Sources
On May 6th, 2026 the market cap of Firebrick Pharma Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $9.47 Million USD |
| MoneyControl | $9.47 Million USD |
| MarketWatch | $9.47 Million USD |
| marketcap.company | $9.47 Million USD |
| Reuters | $9.47 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Firebrick Pharma Ltd
Firebrick Pharma Limited engages in the development and commercialization of povidone-iodine (PVP-I) products under the Nasodine brand in Asia, North America, Europe, and internationally. It offers nasal spray PVP-I products for the treatment of common cold. The company was incorporated in 2012 and is based in Melbourne, Australia.